BUZZ-Australia's Radiopharm Theranostics rises on partnership with Lantheus

** Shares of clinical-stage biopharmaceutical firm Radiopharm Theranostics RAD.AX rise as much as 21.7% to A$0.028, their highest since Dec. 16

** Co inks co-development deal to develop biopharmaceuticals with Massachusetts-based Lantheus LNTH.O in Australia

** Deal includes basket clinical trial targeting multiple solid tumours

** Co to receive up to $2 mln in milestone payments upon achieving key objectives, with the LNTH footing all costs

** Including session's moves, stock trims YTD losses to 64.9% as of 2340 GMT

(Reporting by Kumar Tanishk in Bengaluru)

((Tanishk.Kumar@thomsonreuters.com;))